Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Lévy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P.

Lancet Haematol. 2019 Jul 16. pii: S2352-3026(19)30113-9. doi: 10.1016/S2352-3026(19)30113-9. [Epub ahead of print]

PMID:
31324600
2.

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.

Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, Dilhuydy MS, Nollet D, Guieze R, Feugier P, Roos-Weil D, Willems L, Michallet AS, Delmer A, Hormigos K, Levy V, Cymbalista F, Baran-Marszak F; French Innovative Leukemia Organization (FILO) CLL Group.

Blood. 2019 Aug 15;134(7):641-644. doi: 10.1182/blood.2019000854. Epub 2019 Jun 26.

PMID:
31243043
3.

Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation.

Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Brice P, Morice P, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Gouy S, Chalas C, Egels S, Dhédin N, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N; CAROLéLISA Cooperative Group.

Hum Reprod. 2019 Jun 4;34(6):1083-1094. doi: 10.1093/humrep/dez047.

PMID:
31116405
4.

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R; LYSA.

Eur J Cancer. 2019 Jul;115:47-56. doi: 10.1016/j.ejca.2019.04.006. Epub 2019 May 10.

PMID:
31082693
5.

Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.

Quinquenel A, Godet S, Dartigeas C, Ysebaert L, Dupuis J, Ohanyan H, Collignon A, Gilardin L, Lepretre S, Dilhuydy MS, Vignon M, de Guibert S, Dmytruk N, Durot E, Ghez D, Roos Weil D, Béné MC, Toussaint E, Merabet F, Lévy V, Delmer A, Aurran T.

Am J Hematol. 2019 Jul;94(7):E183-E185. doi: 10.1002/ajh.25480. Epub 2019 Apr 11. No abstract available.

PMID:
30945328
6.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
7.

Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies.

Poirot C, Fortin A, Dhédin N, Brice P, Socié G, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Chalas C, Egels S, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N.

Haematologica. 2019 Aug;104(8):e360-e363. doi: 10.3324/haematol.2018.211094. Epub 2019 Feb 14. No abstract available.

8.

[Isolated digestive localization of Hodgkin lymphoma in an HIV-infected patient, detected after hemophagocytic lymphohistiocytosis].

Romaru J, Lebrun D, Brunet A, Kheirallah S, Cousson J, Delmer A, Bani-Sadr F.

Med Mal Infect. 2019 May;49(3):221-224. doi: 10.1016/j.medmal.2019.01.005. Epub 2019 Jan 25. French. No abstract available.

PMID:
30691919
9.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.

PMID:
30658935
10.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Chaoui D, Hacini M, Fitoussi O, Karlin L, Arkam Y, Jourdan E, Orfeuvre H, Voillat L, Sanhes L, Leprêtre S, Liu KL, Barry M, Tempescul A, Dilhuydy MS, Chaib A, Slama B, Labourey JL, Benbrahim O, Dreyfus B, Mahé B, Maynadié M, Delmer A, Benkanoun C, Boissard F, Gandon S, Veerabudun K, Choquet S; on behalf of the PERLE investigators .

Leuk Lymphoma. 2019 Jun;60(6):1563-1567. doi: 10.1080/10428194.2018.1533130. Epub 2019 Jan 9. No abstract available.

PMID:
30624147
11.

Assessment of silt from sand and gravel processing as a suitable sub-soil material in land restoration: A glasshouse study.

Mašková L, Simmons RW, De Baets S, Montero EM, Delmer A, Sakrabani R.

Chemosphere. 2019 Mar;219:58-65. doi: 10.1016/j.chemosphere.2018.11.155. Epub 2018 Dec 1.

12.

Pulmonary adverse events related to idelalisib therapy: A single centre experience.

Migault C, Lebrun D, Toubas O, Nguyen Y, Giltat A, Julien G, Toubas D, Lebargy F, Delmer A, Bani-Sadr F.

J Chemother. 2018 Sep;30(5):318-322. doi: 10.1080/1120009X.2018.1516184. Epub 2018 Oct 9.

PMID:
30299215
13.

Skeletal involvement of hairy cell leukemia.

Durot E, Quinquenel A, Kleiber JC, Patey M, Bazin A, Delmer A.

Clin Case Rep. 2018 Jul 2;6(8):1651-1652. doi: 10.1002/ccr3.1635. eCollection 2018 Aug.

14.

A neutrophil "Ugly Duckling".

Durot E, Legendre H, Genewe R, Lecoq-Lafon C, Delmer A.

Br J Haematol. 2018 Dec;183(5):701. doi: 10.1111/bjh.15500. Epub 2018 Jul 18. No abstract available.

PMID:
30022484
15.

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G.

Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17.

16.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S.

Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. No abstract available.

17.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.

Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurran T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournilhac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.

Haematologica. 2018 Aug;103(8):e356-e359. doi: 10.3324/haematol.2017.182352. Epub 2018 Mar 8. No abstract available.

18.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
19.

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).

Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A.

Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. No abstract available.

20.

Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.

Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S.

Leuk Lymphoma. 2018 Jul;59(7):1614-1623. doi: 10.1080/10428194.2017.1390236. Epub 2017 Oct 24.

PMID:
29063805
21.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).

Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A.

Br J Haematol. 2017 Nov;179(3):439-448. doi: 10.1111/bjh.14881. Epub 2017 Aug 2.

PMID:
28770576
22.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.

Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12.

23.

[Viral triumvirate].

N'Guyen Y, Didier K, Patey M, Lebrun D, Cousson J, Delmer A, Bani-Sadr F.

Presse Med. 2017 Sep;46(9):880-883. doi: 10.1016/j.lpm.2017.05.024. Epub 2017 Jun 13. French. No abstract available.

PMID:
28623077
24.

Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration.

Hentzien M, Strady C, Vernet-Garnier V, Servettaz A, De Champs C, Delmer A, Bani-Sadr F, N'Guyen Y.

Infect Dis (Lond). 2017 Sep;49(9):664-673. doi: 10.1080/23744235.2017.1323346. Epub 2017 May 11.

PMID:
28490261
25.

Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.

Bidet A, Chollet C, Gardembas M, Nicolini FE, Genet P, Delmer A, Caillot D, Dulucq S, Mahon FX, Lippert E.

Br J Haematol. 2018 Jul;182(1):148-152. doi: 10.1111/bjh.14748. Epub 2017 May 9. No abstract available.

PMID:
28485070
26.

Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report.

Quinquenel A, Maestraggi Q, Lecoq-Lafon C, Peffault de Latour R, Delmer A, Servettaz A.

Medicine (Baltimore). 2017 Mar;96(12):e6403. doi: 10.1097/MD.0000000000006403. Erratum in: Medicine (Baltimore). 2017 Apr 21;96(16):e6706.

27.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29. No abstract available.

28.

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

Chaoui D, Choquet S, Sanhes L, Mahé B, Hacini M, Fitoussi O, Arkam Y, Orfeuvre H, Dilhuydy MS, Barry M, Jourdan E, Dreyfus B, Tempescul A, Leprêtre S, Bardet A, Leconte P, Maynadié M, Delmer A.

Leuk Lymphoma. 2017 Jun;58(6):1366-1375. doi: 10.1080/10428194.2016.1243673. Epub 2017 Feb 9.

PMID:
28271952
29.

The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.

Sarkozy C, Huet S, Carlton VE, Fabiani B, Delmer A, Jardin F, Delfau-Larue MH, Hacini M, Ribrag V, Guidez S, Faham M, Salles G.

Oncotarget. 2017 Jan 31;8(5):8765-8774. doi: 10.18632/oncotarget.14448.

30.

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.

Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Génin M, Mercier M, Dupuis J, Bijou F, Herbaux C, Delmer A, Fabiani B, Besson C, Le Gouill S, Gyan E, Laurent C, Ghesquieres H, Cartron G.

Ann Oncol. 2017 Apr 1;28(4):843-848. doi: 10.1093/annonc/mdw684.

PMID:
28031174
31.

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.

Clin Pharmacokinet. 2017 Jun;56(6):635-647. doi: 10.1007/s40262-016-0470-8.

PMID:
27783363
32.

Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.

Souchet L, Levy V, Ouzegdouh M, Tamburini J, Delmer A, Dupuis J, Le Gouill S, Pégourié-Bandelier B, Tournilhac O, Boubaya M, Vargaftig J, Choquet S, Leblond V; FILO (French Innovative Leukemia Organization).

Am J Hematol. 2016 Aug;91(8):782-6. doi: 10.1002/ajh.24405. Epub 2016 Jun 3.

33.

Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.

Quinquenel A, Sicre de Fontbrune F, Durot E, Pannetier M, Michonneau D, Socié G, Delmer A, Peffault De Latour R.

Br J Haematol. 2017 Mar;176(6):997-999. doi: 10.1111/bjh.14029. Epub 2016 Mar 15. No abstract available.

PMID:
26991435
34.

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.

Assouline S, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, Brewster M, Catalani O, Li S, McIntyre C, Sayyed P, Badoux X.

Lancet Haematol. 2016 Mar;3(3):e128-38. doi: 10.1016/S2352-3026(16)00004-1.

PMID:
26947201
35.

Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.

Bachy E, Estell JA, Van de Neste E, Bouabdallah R, Bargay J, Delmer A, Gelas-Dore B, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Lamy T, Dartigues P, Seymour JF, Salles G.

Am J Hematol. 2016 Jun;91(4):410-5. doi: 10.1002/ajh.24305.

36.

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.

Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, Scime R, Kobbe G, Ferrara F, Delmer A, Sayer H, Amorim S, Bouabdallah R, Finke J, Salles G, Yakoub-Agha I, Faber E, Nicolas-Virelizier E, Facchini L, Vallisa D, Zuffa E, Sureda A, Dreger P; EBMT Lymphoma Working Party.

Bone Marrow Transplant. 2016 Feb;51(2):212-8. doi: 10.1038/bmt.2015.273. Epub 2015 Nov 16.

PMID:
26569093
37.

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study.

Djelbani-Ahmed S, Chandesris MO, Mekinian A, Canioni D, Brouzes C, Hanssens K, Pop G, Durieu I, Durupt S, Grosbois B, Besnard S, Tournilhac O, Beyne-Rauzy O, Agapé P, Delmer A, Ranta D, Jeandel PY, Georgin-Lavialle S, Frenzel L, Damaj G, Eder V, Lortholary O, Hermine O, Fain O, Soussan M.

Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2013-20. doi: 10.1007/s00259-015-3117-3. Epub 2015 Jul 5.

PMID:
26140850
38.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28.

PMID:
26140301
39.

Diagnosis approach of chronic lymphocytic leukemia on unstained blood smears using Raman microspectroscopy and supervised classification.

Happillon T, Untereiner V, Beljebbar A, Gobinet C, Daliphard S, Cornillet-Lefebvre P, Quinquenel A, Delmer A, Troussard X, Klossa J, Manfait M.

Analyst. 2015 Jul 7;140(13):4465-72. doi: 10.1039/c4an02085e.

PMID:
26017101
40.

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.

Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, Catalani O, Hourcade-Potelleret F, Sayyed P, Badoux X.

Br J Clin Pharmacol. 2015 Nov;80(5):1001-9. doi: 10.1111/bcp.12662. Epub 2015 Jul 29.

41.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.

Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L.

Am J Hematol. 2015 Jun;90(6):511-4. doi: 10.1002/ajh.23999. Epub 2015 Apr 1.

42.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.

Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G.

Leukemia. 2015 Jul;29(7):1496-501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.

PMID:
25676424
43.

Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).

Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, Michallet AS, Feugier P, Guieze R, Levy V, Delmer A.

Am J Hematol. 2015 Mar;90(3):204-7. doi: 10.1002/ajh.23909. Epub 2015 Jan 16.

44.

Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study.

Durot E, Michallet AS, Leprêtre S, Le QH, Leblond V, Delmer A.

Eur J Haematol. 2015 Aug;95(2):160-7. doi: 10.1111/ejh.12474. Epub 2015 Jan 21.

PMID:
25359318
45.

Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients.

Quinquenel A, Al Nawakil C, Baran-Marszak F, Eclache V, Letestu R, Khalloufi M, Boubaya M, Le Roy C, Varin-Blank N, Delmer A, Levy V, Ajchenbaum-Cymbalista F.

Am J Hematol. 2015 Jan;90(1):E5-8. doi: 10.1002/ajh.23861. Epub 2014 Oct 25.

46.

Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML.

Sébert M, Porcher R, Robin M, Adès L, Boissel N, Raffoux E, Xhaard A, Dhedin N, Larghero J, Himberlin C, Delmer A, Fenaux P, Dombret H, Socié G, de Latour RP.

Bone Marrow Transplant. 2015 Jan;50(1):74-81. doi: 10.1038/bmt.2014.199. Epub 2014 Sep 22.

PMID:
25243624
47.

Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases.

Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A.

Ann Hematol. 2015 Jan;94(1):89-95. doi: 10.1007/s00277-014-2175-0. Epub 2014 Sep 7.

48.

Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.

Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1905-11. doi: 10.1016/j.bbmt.2014.07.024. Epub 2014 Jul 26.

49.

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X; French Society of Haematology.

Ann Hematol. 2014 Dec;93(12):1977-83. doi: 10.1007/s00277-014-2140-y. Epub 2014 Jul 5.

50.

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA).

Ann Oncol. 2014 Aug;25(8):1622-8. doi: 10.1093/annonc/mdu189. Epub 2014 May 14.

PMID:
24827123

Supplemental Content

Loading ...
Support Center